Ranking

Cheapest Compounded Tirzepatide Online: Entry Price vs What You Pay

The lowest advertised figure is $99 a month. The lowest figure that still applies at a maintenance dose, from a provider that publishes a flat rate and that we captured o

The two answers, and why they differ

Ask for the cheapest compounded tirzepatide and you get $99. That figure is real. It is also the price of about four weeks of treatment.

The tirzepatide label directs 2.5 mg once weekly for four weeks, then increases in 2.5 mg steps no sooner than every four weeks, and states plainly that 2.5 mg is treatment initiation and is not approved as a maintenance dosage. Titration to a maintenance dose runs roughly 20 to 24 weeks.

So a programme that raises its price at each step collects the advertised figure for one month of a treatment the withdrawal evidence suggests is indefinite. In SURMOUNT-4, participants withdrawn from tirzepatide regained 14.0% of body weight over 52 weeks while those continuing lost a further 5.5%.

That is the whole reason this page has two answers instead of one.

What we actually hold, and what we withdrew

Figures we captured at the source ourselves

Seven records. That is the entire set of tirzepatide prices this publication has read at source. Every other figure on the internet for this market is somebody else's capture, or nobody's.

The ten figures we withdrew, and why

Why this happened, in plain terms

We spent several pages criticising other publications for quoting prices without their term, dose and formulation. Then we republished their figures without checking any of the three.

Our evidence model has a status called reported, which means the provider reported it. We applied it to figures no provider had reported to anyone — they were things other websites had written. That is not a labelling nicety. It is the difference between a price and a rumour.

A new status now exists, third-party claim, and figures carrying it cannot be ranked, summed, averaged or compared anywhere on this site. The Embody case shows why: a single number, republished across at least five publications, that does not survive one search.

If you want a figure for any provider below, the honest answer is that you should read it on their own pricing page, on the plan you would sign, at the dose you expect to reach. That is what we did for the seven records above and have not yet done for the rest.

What we can and cannot tell you

We hold captured pricing for six providers and provider-reported figures for the rest. The blanks in the fourth column above are the honest state of this market: most providers do not publish what their programme costs at 10 mg, which is the figure that decides the annual bill.

That is not a criticism of the cheap entries. It is the reason a ranking on the first column is a ranking on a number most patients stop paying after month one.

Where the low figures come from

Introductory rates. Enhance.MD is reported at $99 for the first month and $280 ongoing. Noom Med at $149 first month and $279 ongoing. A first-month figure quoted as the headline is the clearest form of this.

Prepaid annual terms. Several of the lowest advertised figures are annual plans billed yearly up front, or 12-month tiers quoted against a higher month-to-month rate. We have withdrawn the specific numbers we previously published for these providers, because we took them from other publications rather than from the providers' own sites.

Microdose programmes. Several of the low figures are microdose programmes at roughly 1 mg weekly, below the 5, 10 and 15 mg studied in SURMOUNT-1. A microdose programme is a different product, not a discount on a full-dose one.

Dose-tiered ladders. Several programmes advertise a starting-dose rate and escalate at each step. Where we previously published the specific figures, they came from other publications and have been withdrawn.

Five publishers, five prices, same provider

We compiled what five publications reported for the same providers in the same period. The spreads are not small.

Nobody is wrong. Each figure is defensible on its own terms — a prepaid year, a first month, an oral formulation, a higher dose. NexLife (opens nexlife.us in a new tab)'s $29 is the published plan ladder rather than a disagreement, which is the only reason it is narrow.

How to answer this for yourself in one question

Ask any provider: what is the all-in monthly price at 10 mg, on the plan I would actually sign?

A provider that answers with one number has a flat rate. A provider that answers with a range has a ladder, and the range is your real cost. A provider that will not answer before you enrol has told you something too.

We publish the answers we get in our disclosure register.

Before any of this: check coverage

A covered brand GLP-1 commonly lands near $25 a month with a manufacturer savings card, and eligible Medicare enrollees pay $50 through the GLP-1 Bridge until 31 December 2027. Both sit below every figure on this page.

Weight-management coverage is excluded more often than diabetes coverage for the same molecules, so ask about the indication rather than the drug name. Our insurance guide sets out the four questions that settle it.

Questions readers actually ask

Capture standing: 15 of 70 price records in this dataset were read at the source by us: 9 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.